Hot Topics: Impact of Biomarkers in Alzheimer's Disease - Dx-Rx collaboration paves the way for personalized medicine
- Published: December 2011
Written by leading authorities in the field, this book describes the cognitive changes associated with age, the earliest detectable stages of Alzheimer’s, and the relationship of these conditions to MCI. The authors review the latest advances in our understanding of MCI, its prevalence, evaluation, management, and outcomes and in so doing provide practising physicians with a useful resource that assists them in identifying those MCI patients who will progress to recognised Alzheimer’s Disease.
Beautifully presented in full colour, Early Diagnosis and Treatment of Mild Cognitive Impairment includes case studies and discusses future therapeutic and diagnostic strategies. It is an invaluable resource for postgraduates and professionals, for specialist physicians in neurology and psychiatric medicine, geriatric medicine and general practice.
What is mild cognitive impairment?
Epidemiological studies of MCI.
The border zone between aging and dementia: cognitive and neuropathological changes.
Aging and cognitive performance.
2. Neuropathology of Alzheimer’s disease, non-demented aging and MCI.
Topography of neuropathological changes.
Neuropathological AD diagnosis.
Neuropathology of aging.
Neuropathology of MCI.
Does a subset of MCI patients actually have early Alzheimer’s disease?
3. Detecting and diagnosing MCI and early AD.
Recognition of MCI and early AD.
Laboratory and radiological evaluation.
Psychometric/mental status testing.
Mini-mental state examination.
Dementia staging instruments.
Global deterioration scale.
4. Etiology of MCI: differential diagnosis.
Dementia with Lewy bodies.
Frontotemporal lobar dementias.
Identifying the subset of MCI that is AD.
5. Treatment of MCI and dementia.
The case for early treatment.
Agents under investigation for AD treatment and prevention.
Vitamin E and selegiline.
6. Future therapeutic and diagnostic strategies.
CSF amyloid beta (Aß).
CSF markers of inflammation.
CSF markers of oxidative stress.
PET and SPECT.
Functional MRI (fMRI).
Early-onset familial AD.
Amyloid precursor protein.
7. Case studies.
Case report 1: MCI as early-stage Alzheimer’s disease.
Case report 2: Diagnosis of dementia prior to impairment sufficient for MCI.
Case report 3: Memory complaints associated with non-demented aging.
Dr Burns is an Assistant Professor in the Department of Neurology at the University of Kansas Medical Center. He is the Director of the Alzheimer and Memory Center and the Alzheimer’s Disease Clinical Research Program and serves as the Principal Investigator of the Brain Aging Program.